Search





Search





Markets
/
Stocks
/
nasdaq-imux
/

Immunic Inc

IMUX

Add to Watchlist

11.660USD

-0.420-3.48%

Close 05/18, 16:00（ET）Quotes delayed by 15 min

158.83MMarket Cap

LossP/E TTM



Immunic Inc

11.660

-0.420-3.48%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Immunic Inc

Currency: USD Updated: 2026-05-18

Key Insights

Immunic Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 56 out of 381 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 49.00.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Immunic Inc's Score

Industry at a Glance

Industry Ranking

56 / 381

Overall Ranking

163 / 4479

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Immunic Inc Highlights

StrengthsRisks

Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.

Fairly Valued

The company’s latest PE is -0.80, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 58.68M shares, increasing 27.51% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 0.00 shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.10.

Analyst Rating

Based on 9 analysts

Buy

Current Rating

49.000

Target Price

+305.63%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-18

The current financial score of Immunic Inc is 7.02, ranking 137 out of 381 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.02

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.30

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Immunic Inc's Company Valuation

Currency: USD Updated: 2026-05-18

The current valuation score of Immunic Inc is 8.17, ranking 58 out of 381 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.80, which is -62.88% below the recent high of -0.30 and -2048.09% above the recent low of -17.22.

Score

Industry at a Glance

Previous score

8.17

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 56/381

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-18

The current earnings forecast score of Immunic Inc is 8.89, ranking 35 out of 381 in the Biotechnology & Medical Research industry. The average price target is 4.00, with a high of 10.00 and a low of 3.00.

Score

Industry at a Glance

Previous score

8.89

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 9 analysts

Buy

Current Rating

49.000

Target Price

+305.63%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Immunic Inc

IMUX

CRISPR Therapeutics AG

CRSP

Beigene Ltd

ONC

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-18

The current price momentum score of Immunic Inc is 9.26, ranking 12 out of 381 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 13.81 and the support level at 9.01, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.45

Change

-0.19

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.363

Buy

RSI(14)

53.318

Neutral

STOCH(KDJ)(9,3,3)

58.538

Sell

ATR(14)

0.997

High Vlolatility

CCI(14)

38.519

Neutral

Williams %R

38.643

Buy

TRIX(12,20)

0.535

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

12.249

Sell

MA10

11.892

Sell

MA20

10.778

Buy

MA50

11.374

Buy

MA100

9.427

Buy

MA200

8.732

Buy

Institutional Confidence

Currency: USD Updated: 2026-05-18

The current institutional shareholding score of Immunic Inc is 5.00, ranking 134 out of 381 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 57.65%, representing a quarter-over-quarter increase of 17.63%. The largest institutional shareholder is The Vanguard, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

abrdn Inc.

8.24M

BVF Partners L.P.

7.59M

-0.81%

Millennium Management LLC

3.42M

+544.58%

Avidity Partners Management LP

4.70M

Soleus Capital Management, L.P.

4.50M

Nantahala Capital Management, LLC

4.38M

Laurion Capital Management LP

3.88M

+106.26%

Alyeska Investment Group, L.P.

3.75M

Focus Partners Wealth, LLC

2.62M

+1.58%

Risk Assessment

Currency: USD Updated: 2026-05-18

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Immunic Inc. The Biotechnology & Medical Research industry's average is 3.36. The company's beta value is 1.24. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.